RT Journal Article SR Electronic T1 Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 632 OP 635 DO 10.2967/jnumed.117.196329 VO 59 IS 4 A1 Frederik L. Giesel A1 Leon Will A1 Claudia Kesch A1 Martin Freitag A1 Christophe Kremer A1 Jonas Merkle A1 Oliver C. Neels A1 Jens Cardinale A1 Boris Hadaschik A1 Markus Hohenfellner A1 Klaus Kopka A1 Uwe Haberkorn A1 Clemens Kratochwil YR 2018 UL http://jnm.snmjournals.org/content/59/4/632.abstract AB Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results: 18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007–positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007–positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.